Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study - PubMed
4 hours ago
- #urothelial carcinoma
- #immune checkpoint blockade
- #real-world study
- Study assesses real-world efficacy of anti-PD-(L)1 monotherapy for advanced urothelial carcinoma with histologic variants (UC-V) and non-urothelial carcinomas (NUC).
- 129 UC-V and 34 NUC patients treated after platinum-based chemotherapy failure showed median overall survival of 8.6 months and progression-free survival of 2.6 months.
- Objective response rate was 31.4%, with 15.3% complete response and 16.1% partial response.
- ECOG performance status ≥ 2 independently correlated with worse survival outcomes, while pembrolizumab improved progression-free survival.
- Grade ≥ 3 immune-related adverse events occurred in 10.8% of patients, with no treatment-related deaths.
- Anti-PD-(L)1 therapy demonstrates clinical benefit in these aggressive subtypes after platinum failure.